Request Sample
Request Methodology
Description
The mammography workstations market is anticipated to be valued at USD 53.5 million in 2021 and is expanded to grow at a significant CAGR of 5.2% over 2022-2028. With the growing prevalence of breast cancer, technological advancements such as digital mammography, optical imaging, molecular breast imaging, electrical impedance, and tomosynthesis fuelled the global mammography workstations market. The continuous development and refinement of imaging systems and software can help lead to an early-stage diagnosis. Currently, most hospitals are shifting from 2D mammography systems to 3D mammography devices. In comparison with other available technologies on the market, 3D tomosynthesis has been identified as the fastest-growing for breast imaging, offering increased efficiency and higher diagnostic accuracy. For instance, At the recent 2018 Society for Breast Imaging (SBI)/American College of Radiology (ACR) Breast Imaging Symposium in Las Vegas, many current technologies were being showcased on the show floor. Hologic’s Clarity HD high-resolution 3-D imaging and Intelligent 2-D imaging technology recently received FDA premarket approval (PMA) and are now available on the 3Dimensions breast tomosynthesis system. Hologic’s Clarity HD high-resolution 3-D imaging and Intelligent 2-D imaging technology recently received FDA premarket approval (PMA) and are now available on the 3Dimensions breast tomosynthesis system. In 2020, multimodality mammography stations accounted for a larger revenue share and were projected to grow with a CAGR of 83.2% from 2022 to 2028 to reach USD 60.7 Mn by 2028. The segment’s high market share is primarily due to the increased usage of these devices in hospitals and breast care centers. The multimodality workstation provides a high-resolution display and can compare two-dimensional display and tomosynthesis images.
Recent Market Developments:
In May 2021, GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients.
In December 2020, Hologic Receives FDA Clearance for Latest Breakthrough in Early Breast Cancer Detection, Genius AI™ Detection.
